Compare
Summit Therapeutics Inc. vs Kiniksa Pharmaceuticals International, plc vs Kura Oncology, Inc. vs Cryoport, Inc.
| Latest fiscal year | Summit Therapeutics Inc. SMMT | Kiniksa Pharmaceuticals International, plc KNSA | Kura Oncology, Inc. KURA | Cryoport, Inc. CYRX |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $677.56M | $67.48M | $176.18M |
| Revenue growth (YoY) | n/a | +60.1% | +25.2% | +12.4% |
| Gross margin | n/a | 88.5% (computed) | n/a | 47.1% |
| Operating margin | n/a | 11.4% | -449.9% | -20.9% |
| Net margin | n/a | 8.7% | -412.9% | 44.4% |
| Net income | -$1.08B | $59.01M | -$278.67M | $78.30M |
| EPS (Diluted) | -$1.44 | $0.75 | -$3.18 | $1.40 |
| Operating cash flow | -$322.93M | $137.99M | -$64.06M | -$8.58M |
| Free cash flow | -$323.59M | $136.42M | -$70.70M | -$25.02M |
| Cash & equivalents | $225.27M | $165.60M | $149.10M | $250.49M |
| Total assets | $751.18M | $763.63M | $738.36M | $764.99M |
| Total liabilities | $92.32M | $196.03M | $564.23M | $262.35M |
| Shareholders' equity | $658.86M | $567.61M | $174.13M | $502.64M |
| Return on year-end equity | -163.9% | 10.4% | -160.0% | 15.6% |
| Shares outstanding | 775.37M | n/a | 87.86M | 49.85M |
Revenue, most recent five fiscal years
| Fiscal year | Summit Therapeutics Inc. | Kiniksa Pharmaceuticals International, plc | Kura Oncology, Inc. | Cryoport, Inc. |
|---|---|---|---|---|
| Latest | $0 Ended 2024-12-31 | $677.56M Ended 2025-12-31 | $67.48M Ended 2025-12-31 | $176.18M Ended 2025-12-31 |
| 1 year earlier | $0 Ended 2023-12-31 | $423.24M Ended 2024-12-31 | $53.88M Ended 2024-12-31 | $156.77M Ended 2024-12-31 |
| 2 years earlier | $705.0K Ended 2022-12-31 | $270.26M Ended 2023-12-31 | $0 Ended 2023-12-31 | $168.66M Ended 2023-12-31 |
| 3 years earlier | $1.81M Ended 2021-12-31 | $220.18M Ended 2022-12-31 | n/a | $237.28M Ended 2022-12-31 |
| 4 years earlier | $860.0K Ended 2020-12-31 | $38.54M Ended 2021-12-31 | n/a | $222.61M Ended 2021-12-31 |